DNA Microarray Gene Expression Analysis for Neuropsychiatric Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods have limited progress in identifying gene sequences and gene products responsible for psychotic disorders such as schizophrenia and mood disorders like major depression and bipolar disorder, despite their complex genetic origins.
Innovation Solution
The use of DNA microarrays to study expression profiles in specific brain regions of post-mortem brains from schizophrenia patients, identifying differentially expressed genes and single nucleotide polymorphic markers, which can serve as biomarkers for diagnosis and treatment targets.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If DNA microarrays are used to study gene expression profiles in brain regions, then diagnostic and therapeutic tools for mental disorders can be identified, but the complexity of the genetic basis of these disorders makes progress slow and difficult
Solution Approach 1:
The patent divides the complex brain into specific regions of interest (anterior cingulate cortex, dorsolateral prefrontal cortex, cerebellar cortex, superior temporal gyrus, parietal cortex, nucleus accumbens, amygdala, hippocampus) and analyzes gene expression profiles in each region separately. This segmentation allows the complex genetic data to be managed and interpreted more effectively by focusing on specific brain pathways and circuits associated with mental disorders.
Solution Approach 2:
The patent uses DNA microarrays as an intermediary tool to bridge the gap between complex genetic data and clinical diagnosis. The microarrays provide a systematic way to measure gene expression levels across multiple genes and brain regions simultaneously, transforming complex molecular data into actionable diagnostic and therapeutic information.
2Reliability
If gene expression analysis is performed in multiple brain regions and lymphocytes, then comprehensive diagnostic markers can be identified, but the time required for analysis increases
Solution Approach 1:
The patent employs DNA microarrays that can simultaneously analyze gene expression in multiple brain regions and lymphocytes within a single assay system. This multi-functionality allows comprehensive diagnostic marker identification without proportionally increasing analysis time, as the same microarray platform and analytical methods are used across all tissue types.
Solution Approach 2:
The patent identifies and validates diagnostic markers and gene expression profiles in advance through pre-mortem analysis of post-mortem brain tissues and lymphocyte samples. By performing these analyses beforehand and establishing reference ranges, the actual diagnostic process can be accelerated when applied to new patients.
3Adaptability or versatility
If single nucleotide polymorphic markers and biomarkers are identified, then treatment targets can be determined, but the difficulty of detecting and measuring these markers increases
Solution Approach 1:
The patent replaces complex mechanical and manual detection methods with automated DNA microarray technology and computational analysis algorithms. This substitution enables high-throughput screening and precise measurement of single nucleotide polymorphic markers and gene expression levels, significantly reducing the difficulty of detection while improving reproducibility.
Solution Approach 2:
The patent utilizes changes in gene expression parameters (upregulation, downregulation, differential expression) between control and patient samples to identify diagnostic and therapeutic markers. By focusing on relative changes rather than absolute values, the detection becomes more robust and less sensitive to technical variations in the measurement process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for differential gene expression analysis in brain regions and lymphocytes, providing diagnostic and therapeutic tools for mental disorders, including the identification of lithium-responsive genes and potential drug targets for treatment.
Implementation Method 1
The DNA microarrays were probed with fluorescently labeled cDNAs or cRNA
Implementation Method 2
contacting the sample with a reagent that selectively associates with a polynucleotide or polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to a nucleotide sequence listed in FIGS. 1-14
Data Source
AI summary
The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders.